• Chikara Kunisaki, Hirochika Makino, Jun Kimura, Ryo Takagawa, Amane Kanazawa, Mitsuyoshi Ota, Takashi Kosaka, Hidetaka A Ono, Hirotoshi Akiyama, and Itaru Endo.
• Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Japan.
• Oncology. 2015 Jan 1; 88 (5): 281-8.

ObjectiveThis retrospective study aimed to address the therapeutic outcome for scirrhous gastric cancer patients by evaluating the effect of neoadjuvant chemotherapy prior to gastrectomy.MethodsTwo cycles of a 3-week regimen of fluoropyrimidine S-1 (40 mg/m(2), orally, twice daily), together with cisplatin (60 mg/m(2), intravenously, day 8), were administered to patients, separated by a 2-week rest period. Surgery was performed 3 weeks later in the neoadjuvant group (n = 27). We retrospectively evaluated overall survival and prognostic factors in these patients.ResultsUnivariate analysis showed that positive lavage cytology indicated significantly worse prognoses. In the 15 patients who also underwent curative gastrectomies after S-1 plus cisplatin chemotherapy, the pathological response grade was a significant prognostic factor for 5-year survival. Additionally, lymph node metastasis tended to be an adverse prognostic factor.ConclusionAfter S-1 plus cisplatin neoadjuvant chemotherapy, a grade 2-3 pathological response may predict favorable outcomes in scirrhous gastric cancer patients receiving curative gastrectomy, but further studies are needed to confirm these results.2015 S. Karger AG, Basel

45 keywords...

hide…